Alnylam gets surprise FDA rejection for rare disease drug
In a surprise move, the U.S. Food and Drug Administration rejected a drug made by Alnylam Pharmaceuticals Inc., citing a lack of"clinical meaningfulness."
The agency rejected the advice of its own advisory committee in doing so. Last month, a group of experts9-3 to endorse the drug, patisiran, as a treatment for cardiomyopathy of hereditary transthyretin-mediated amyloidosis, a rare disease that causes a buildup of amyloid proteins outside the cells. Still, clinical meaningfulness of benefit on various metrics was"the subject of rich debate" during the meeting, as Leerink Partners analyst Mani Foroohar wrote in a research note.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Tumor-destroying sound waves receive FDA approval for liver treatment in humansThe U.S. Food and Drug Administration has approved the use of sound waves to break down tumors—a technique called histotripsy—in humans for liver treatment.
Weiterlesen »
Connections between rare genetic changes and blood proteins to shape current and future drug discoveryResearch published in Nature provides new insight into human disease by studying how rare changes in genes affect proteins found in human blood, called plasma proteins. Findings revealed thousands of never-before-identified associations between these rare genetic variants and plasma proteins, the basis of which will inform future drug discovery research and treatment approaches.
Weiterlesen »
Gary Lineker among pundits hailing Leeds United loanee Jack HarrisonCatch up on the latest Leeds United headlines as the October international break gets under way
Weiterlesen »